Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study.

Díaz-Cerezo S, Artime E, Redondo-Antón J, Duque N, Spaepen E, Mangas Cruz MÁ, Arnas-Leon C, Olveira G, Rodríguez IR, Julián Alagarda MT, Valdés N, Merchante AÁ, Masmiquel L, Rubio-de Santos M

Patient preference and adherence1 May 2025

PMID40330535PMCIDPMC12053930DOI10.2147/ppa.s509483PepBankPUB-40330535

Read at source PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studyOther
In adults with type 2 diabetes, compliance with all instructions was 90.4% with daily oral semaglutide versus 96.8% with weekly injectable dulaglutide.
In plain wordsIn adults with diabetes, oral semaglutide was linked to lower instruction compliance than dulaglutide, at 90.4% versus 96.8%.
Peptide
Semaglutide
Outcome
DecreaseCompliance with all administration instructions
Study
n = 230
Comparator
Weekly injectable dulaglutide
Outcome group
Treatment adherence and retention · Pharmacology
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Compliance
90.4%
oral semaglutide
Compliance
96.8%
dulaglutide
Source sentences
Summary
More participants treated with weekly injectable dulaglutide (96.8%) than participants treated with daily oral semaglutide (90.4%) were compliant with all package leaflet administration instructions.
3 context sentences(design, population, supporting numbers)
Summary · context
This was an observational cross-sectional study conducted in Endocrinology Units in Spain.
Summary · context
Patients with T2D receiving weekly injectable dulaglutide or daily oral semaglutide at study enrolment who had initiated treatment 3-12 months before were consecutively recruited during routine visits.
Summary · context
A total of 95 participants treated with weekly injectable dulaglutide and 135 participants treated with daily oral semaglutide were evaluated.
Report a problemFND-4033053502
02HumanObservational studyOther
In adults with type 2 diabetes, oral semaglutide was linked to lower adjusted compliance than dulaglutide; the dulaglutide-to-semaglutide odds ratio was 3.2.
In plain wordsIn adults with diabetes, oral semaglutide was linked to lower adjusted instruction compliance than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseAdjusted odds of instruction compliance
Study
n = 230
Comparator
Weekly injectable dulaglutide
Outcome group
Treatment adherence and retention · Pharmacology
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Odds ratio
3.2 ratio
dulaglutide versus oral semaglutide
95% confidence interval
1.4 to 21.3 ratio
adjusted compliance odds ratio
Source sentences
Summary
After adjusting for potential between-group imbalances, higher compliance in the weekly injectable dulaglutide group compared with the daily oral semaglutide group was observed (odds ratio=3.2, 95% confidence interval 1.4-21.3).
3 context sentences(design, population, supporting numbers)
Summary · context
This was an observational cross-sectional study conducted in Endocrinology Units in Spain.
Summary · context
Patients with T2D receiving weekly injectable dulaglutide or daily oral semaglutide at study enrolment who had initiated treatment 3-12 months before were consecutively recruited during routine visits.
Summary · context
A total of 95 participants treated with weekly injectable dulaglutide and 135 participants treated with daily oral semaglutide were evaluated.
Report a problemFND-4033053504

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In adults with type 2 diabetes, compliance with all instructions was 96.8% with weekly injectable dulaglutide versus 90.4% with daily oral semaglutide.
In plain wordsIn adults with diabetes, dulaglutide was linked to higher instruction compliance than oral semaglutide, at 96.8% versus 90.4%.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCompliance with all administration instructions
Study
n = 230
Comparator
Daily oral semaglutide
Outcome group
Treatment adherence and retention · Pharmacology
Measurements
Compliance
96.8%
dulaglutide
Compliance
90.4%
oral semaglutide
Source sentences
Summary
More participants treated with weekly injectable dulaglutide (96.8%) than participants treated with daily oral semaglutide (90.4%) were compliant with all package leaflet administration instructions.
3 context sentences(design, population, supporting numbers)
Summary · context
This was an observational cross-sectional study conducted in Endocrinology Units in Spain.
Summary · context
Patients with T2D receiving weekly injectable dulaglutide or daily oral semaglutide at study enrolment who had initiated treatment 3-12 months before were consecutively recruited during routine visits.
Summary · context
A total of 95 participants treated with weekly injectable dulaglutide and 135 participants treated with daily oral semaglutide were evaluated.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4033053501
04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In adults with type 2 diabetes, dulaglutide was linked to higher adjusted compliance odds than oral semaglutide, with odds ratio 3.2.
In plain wordsIn adults with diabetes, dulaglutide was linked to higher adjusted instruction compliance than oral semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAdjusted odds of instruction compliance
Study
n = 230
Comparator
Daily oral semaglutide
Outcome group
Treatment adherence and retention · Pharmacology
Measurements
Odds ratio
3.2 ratio
dulaglutide versus oral semaglutide
95% confidence interval
1.4 to 21.3 ratio
adjusted compliance odds ratio
Source sentences
Summary
After adjusting for potential between-group imbalances, higher compliance in the weekly injectable dulaglutide group compared with the daily oral semaglutide group was observed (odds ratio=3.2, 95% confidence interval 1.4-21.3).
3 context sentences(design, population, supporting numbers)
Summary · context
This was an observational cross-sectional study conducted in Endocrinology Units in Spain.
Summary · context
Patients with T2D receiving weekly injectable dulaglutide or daily oral semaglutide at study enrolment who had initiated treatment 3-12 months before were consecutively recruited during routine visits.
Summary · context
A total of 95 participants treated with weekly injectable dulaglutide and 135 participants treated with daily oral semaglutide were evaluated.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4033053503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study.

Summary

Results from this study4

Studies that did not test the peptide alone2

Version history

Subjects

Publication types

Keywords